Inclusion of rituximab in treatment protocols for non-hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy

Oncologist

Volumn 15, Issue 11, 2010, Pages 1214-1219

  Tuccori, Marco ^a,b   Focosi, Daniele ^a   Blandizzi, Corrado ^a,b   Pelosini, Matteo ^a   Montagnani, Sabrina ^a,b   Maggi, Fabrizio ^a   Pistello, Mauro ^a   Antonioli, Luca ^a   Fornai, Matteo ^a   Pepe, Pasquale ^c   Rossi, Giuseppe ^c   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Tuscan Regional Centre of Pharmacovigilance   (Italy)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

JCV; Monoclonal antibody; Non Hodgkin's lymphoma; Progressive multifocal leukoencephalopathy; Rituximab

Indexed keywords

RITUXIMAB;

ADULT; ARTICLE; BRAIN BIOPSY; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK;

EID: 78649943747     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0098     Document Type: Article

References (19)

1. Molloy ES, Calabrese LH. Therapy: Targeted but not trouble-free: Efali-zumab and PML. Nat Rev Rheumatol 2009;5:418-419.
2. Major EO. Reemergence of PML in natalizumab-treated patients-new cases, same concerns. N Engl J Med 2009;361:1041-1043.
3. Carson KR, Focosi D, Major EO et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with ritux-imab, natalizumab, and efalizumab: A review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 2009;10: 816-824.
4. Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009;8:223-235.
5. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoen-cephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-4840.
6. Tuccori M, Focosi D, Maggi F et al. Progressive multifocal leukoenceph-alopathy: A report of three cases in HIV-negative patients with non-Hodgkin's lymphomas treated with rituximab. Ann Hematol 2010;89:519-522.
7. Pelosini M, Focosi D, Rita F et al. Progressive multifocal leukoencepha-lopathy: Report of three cases in HIV-negative hematological patients and review of literature. Ann Hematol 2008;87:405-412.
8. Tuccori M, Focosi D, Blandizzi C et al. Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:1288-1289.
9. Engsig FN, Hansen AB, Omland LH et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: A nationwide cohort study. J Infect Dis 2009;199:77-83.
10. Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1861.
11. Swerdlow SH, Campo E, Harris N. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC, 2008:124-126.
12. Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: Defining a consensus terminology. J Neurovirol 2003;9(suppl 1):88-92.
13. Oberlander TF, Warburton W, Misri S et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and ben-zodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83:68-76.
14. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ 1998;316:989-991.
15. Kraemer HC, Measelle JR, Ablow JC et al. A new approach to integrating data from multiple informants in psychiatric assessment and research: Mixing and matching contexts and perspectives. Am J Psychiatry 2003;160: 1566-1577.
16. Armitage P, Berry G, Matthews J. Statistical Methods in Medical Research, Fourth Edition. Oxford, U.K.: Blackwell, 2002:1-817.
17. Vidal L, Gafter-Gvili A, Leibovici L et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248-255.
18. Goldberg SL, Pecora AL, Alter RS et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peri-transplantation rituximab. Blood 2002;99:1486-1488.
19. U.S. Food and Drug Administration. Rituximab (Marketed as Rituxan): Progressive multifocal leukoencephalopathy (PML). Available at http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm115974.htm, accessed July 31, 2010.